

DEPARTMENT OF THE AIR FORCE

HEADQUARTERS UNITED STATES AIR FORCE WASHINGTON DC

JUN 2 8 2013

MEMORANDUM FOR AFMOA/CC ALL MAJCOM/SG

FROM: AF/SG3

SUBJECT: Guidance on the Use of Japanese Encephalitis Vaccine

ASD(HA) recently published guidance on the use of Japanese Encephalitis (JE) vaccine (attached), based on recommendations from the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP). These guidelines will be used for administration of the JE vaccine, available as the vero cell culture—derived JE vaccine (JE-VC [manufactured as Ixiaro]). Individuals deploying to areas in Pacific Command (PACOM) should be administered JE-VC in accordance with the latest PACOM Force Health Protection Guidance. Individuals for whom JE-VC is highly recommended or recommended will be counseled about vaccination and the vaccine decision should be documented in the medical record.

Individuals who require or who elect to receive JE-VC will be identified as part of an immunization group in ASIMS. A booster dose of JE-VC should be administered after one year if risk of exposure continues. On 1 Jul 2013, individuals who received JE-VC more than one year ago and who remain at risk will be designated "due" (yellow) in ASIMS. On 1 Sep 2013, those who have not received the booster dose will become "overdue" (red). Timing of additional booster doses has not yet been determined by ACIP.

JE-VC was recently approved for children ages 2 months and older. JE vaccine administration in children between the ages of two months and 17 years should also be administered in accordance with ACIP recommendations and documented in the medical record.

The AF/SG point of contact is Lt Col Catherine Witkop, SG3PM, 703-681-7161, DSN 761-7161 or catherine.witkop@pentagon.af.mil.

CHARLES E. POTTER

Brigadier General, USAF, MSC

Assistant Surgeon General, Health Care Operations

Attachment:

1. Guidance on the use of Japanese Encephalitis Vaccine